

# Trials Give Nod to Antibiotics for Certain AOM

BY DOUG BRUNK

FROM NEW ENGLAND JOURNAL  
OF MEDICINE

Children with a certain diagnosis of acute otitis media who were treated with amoxicillin-clavulanate recovered more quickly, compared with those who received placebo, results from two large, separate studies demonstrated. The findings, conducted by research-

ers at the University of Pittsburgh and at the University of Turku, Finland, provide the strongest evidence to date supporting a regimen of antimicrobial therapy in children with a certain diagnosis of acute otitis media (AOM).

"A study with an appropriate design was needed to resolve the controversy regarding antimicrobial therapy versus observation in children with certain diagnoses of acute otitis media," Dr.

Jerome O. Klein of the department of pediatrics at Boston University, wrote in an editorial about the studies (N. Engl. J. Med. 2011;364:168-9). "The investigators in both Pittsburgh and Turku have provided such a study. They performed randomized, blinded trials of the use of amoxicillin-clavulanate as compared with placebo in the age group at greatest risk."

In 2004, the American Academy of

Pediatrics and the American Academy of Family Physicians issued a clinical practice guideline that endorsed initial observation as an option in children aged 6-23 months with mild otalgia and a temperature of less than 39° C in the last 24 hours, and in whom the diagnosis of AOM is uncertain (Pediatrics 2004;113:1451-65).

However, those recommendations were based on previous clinical trials that contained "substantial limitations,"

## Trials Are Well Designed

Prior clinical studies have compared the outcome of AOM treated with antibiotics to that with placebo and have in general reported a more rapid resolution of signs and/or symptoms of AOM in the antibiotic-treated cohort. What is new?

First, both studies employed stringent criteria for entry ensuring that most, if not all, had AOM. Second, the choice and dose of amoxicillin-clavulanate provided coverage based on pharmacokinetic-pharmacodynamic principles for the majority of pneumococcal and *Haemophilus* isolates in each community. Thirdly, the study protocol provided for a sufficient frequency of follow-up to address the primary outcome (time to resolution in Pittsburgh and time to treatment failure in Turku). The results, a high rate of treatment failure in the placebo groups in both studies, distinguish these trials from several recent clinical trials and detail the potential advantages of effective antimicrobial therapy on the resolution of signs and symptoms.

Will these results change our approach to young children with AOM? As most episodes are currently treated with antibiotics, presumably these results will reinforce that approach. But these results also should challenge clinicians to further develop their diagnostic approach to AOM with greater emphasis on physical exam and to emphasize close follow-up for children who are initially managed with symptomatic care only.

DR. STEPHEN I. PELTON is with the division of pediatric infectious diseases at Boston Medical Center. He said he had no relevant financial disclosures.



VIEW ON THE NEWS

## You can help her flourish with all 4 doses

Give her proven protection with  
the only DTaP-IPV/Hib<sup>a</sup> vaccine<sup>1-4</sup>

### Pertussis still poses a threat

The 2008 NIS data show that by 24 months of age, 1 in 5 children did not receive their fourth dose of DTaP vaccine.<sup>5</sup> This leaves children 6 months behind the recommended immunization schedule and vulnerable to potentially devastating diseases.<sup>6</sup>

### You can help enhance compliance

According to the AAP<sup>b</sup>, administering a combination vaccine may enhance timeliness and compliance.<sup>7</sup>

### Pentacel vaccine:

- Contains a Hib component, so it fits easily into the primary series at 2, 4, 6, and 15-18 months of age<sup>1,6</sup>
- Can save a shot at the crowded toddler visit<sup>6,8</sup>

Four doses of Pentacel vaccine constitute a primary pertussis immunization series. Children should receive a fifth dose of DTaP at 4-6 years of age.<sup>1</sup>

To learn more about the efficacy, convenience,  
and safety of Pentacel vaccine,  
please visit [pentacel.com](http://pentacel.com).

To order Pentacel vaccine, log onto  
[VaccineShope.com](http://VaccineShope.com)<sup>®</sup> or call 1-800-VACCINE  
(1-800-822-2463).

15-18 months



according to researchers from one of the studies, who were led by Dr. Alejandro Hoberman of the department of pediatrics at the University of Pittsburgh (N. Engl. J. Med. 2011;364:105-15).

These include “the lack of stringent diagnostic criteria, the inclusion of very young children, and the use of an antimicrobial drug that had limited efficacy or that was administered in suboptimal doses. Moreover, rates of spontaneous improvement similar to the rates seen in those studies among children receiving placebo have not been found uniformly. Therefore, for children with acute otitis

media, the circumstances in which immediate antimicrobial treatment is the preferred strategy have remained unclear,” they said.

Dr. Hoberman, who is also vice chair of clinical research at Children’s Hospital of Pittsburgh, and his associates randomized 291 children aged 6-23 months who were diagnosed with AOM to receive amoxicillin-clavulanate or placebo for 10 days. To meet eligibility for the trial, the children were required to have received at least two doses of pneumococcal conjugate vaccine and to have AOM that was diagnosed based on one of three criteria: onset of

symptoms within 48 hours that parents rated with a score of at least 3 on the Acute Otitis Media Severity of Symptoms (AOM-SOS) scale; the presence of middle-ear effusion; and moderate or marked bulging of the tympanic membrane or slight bulging accompanied by either otalgia or marked erythema of the membrane.

A significantly higher proportion of children who received amoxicillin-clavulanate had initial clearance within 7 days, compared with their counterparts in the placebo group (35% vs. 28%, respectively by day 2; 61% vs. 54% by day 4; and 80% vs. 74% by day 7). A similar relationship was seen

in terms of sustained resolution of symptoms (20% vs. 14% by day 2; 41% vs. 36% by day 4; and 67% vs. 53% by day 7).

The rate of clinical failure, which was defined as the persistence of signs of acute infection on otoscopic evaluation, was less likely in the children who received amoxicillin-clavulanate, compared with those who received placebo (4% vs. 23%, respectively, at or before the visit on day 4 or 5; and 16% vs. 51% at or before the visit on days 10-12).

Dr. Hoberman and his associates concluded that treatment with amoxicillin-

*Continued on page 19*

**sanofi pasteur**

The vaccines division of sanofi-aventis Group

## Indication

Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to *Haemophilus influenzae* type b. Pentacel vaccine is approved for use as a 4-dose series in children 6 weeks through 4 years of age (prior to fifth birthday).

## Safety Information

The most common local and systemic adverse reactions to Pentacel vaccine include injection site redness, swelling, and tenderness; fever, fussiness, and crying. Other adverse reactions may occur. Known systemic hypersensitivity reaction to any component of Pentacel vaccine or a life-threatening reaction after previous administration of the vaccine or a vaccine containing the same substances are contraindications to vaccination.

The decision to give Pentacel vaccine should be based on the potential benefits and risks; if Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid; or if adverse events have occurred in temporal relation to receipt of pertussis-containing vaccine. Encephalopathy within 7 days of administration of a previous dose of a pertussis-containing vaccine or a progressive neurologic disorder is a contraindication. Vaccination with Pentacel vaccine may not protect all individuals.

**Before administering Pentacel vaccine, please see accompanying brief summary of full Prescribing Information.**

## CPT<sup>®</sup> Code: 90698

<sup>a</sup> DTaP = Diphtheria, tetanus, and acellular pertussis; IPV = Inactivated poliovirus; Hib = *Haemophilus influenzae* type b. <sup>b</sup> AAP = American Academy of Pediatrics. <sup>c</sup> CPT = Current Procedural Terminology is a registered trademark of the American Medical Association.

Pentacel vaccine is manufactured by Sanofi Pasteur Limited and Sanofi Pasteur SA and distributed by Sanofi Pasteur Inc.

**References:** 1. Pentacel vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.; 2009. 2. Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate *Haemophilus influenzae* type b vaccines. *J Pediatr.* 1992;120:184-189. 3. Granoff DM, Anderson EL, Osterholm MT, et al. Differences in the immunogenicity of three *Haemophilus influenzae* type b conjugate vaccines in infants. *J Pediatr.* 1992;121:187-194. 4. Greenberg DP, Lieberman JM, Marcy SM, et al. Enhanced antibody responses in infants given different sequences of heterogeneous *Haemophilus influenzae* type b conjugate vaccines. *J Pediatr.* 1995;126:206-211. 5. Centers for Disease Control and Prevention (CDC). Estimated vaccination coverage with individual vaccines and selected vaccination series before 24 months of age by state and local area US, National Immunization Survey, 2008. [http://www2a.cdc.gov/nip/coverage/nis/nis\\_iap2.asp?fmt=v&rpt=tab09\\_24mo\\_iap&qtr=Q1/2008-Q4/2008](http://www2a.cdc.gov/nip/coverage/nis/nis_iap2.asp?fmt=v&rpt=tab09_24mo_iap&qtr=Q1/2008-Q4/2008). Accessed October 12, 2010. 6. CDC. Recommended immunization schedules for persons aged 0 through 18 years—United States, 2010. *MMWR.* 2010;58(51&52):1-4. 7. American Academy of Pediatrics. Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). *Pediatrics.* 1999;103:1064-1077. 8. Food and Drug Administration. Pentacel<sup>®</sup>: DTaP-IPV/Hib Combined (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and *Haemophilus b* conjugate [tetanus toxoid conjugate] vaccine combined). VRBPAC Briefing Document. <http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4275B1-01.pdf>. Accessed October 12, 2010.



**Pentacel<sup>®</sup>**

**Diphtheria and Tetanus Toxoids and  
Acellular Pertussis Adsorbed, Inactivated  
Poliovirus and Haemophilus b Conjugate  
(Tetanus Toxoid Conjugate) Vaccine**

**Protection To Grow On**



Continued from page 17

clavulanate for 10 days in children aged 6-23 months with AOM “affords a measurable short-term benefit, irrespective of the apparent severity of the illness. The benefit must be weighed against concern not only about the side effects of the medication but also about the contribution of antimicrobial treatment to the emergence of bacterial resistance. These considerations underscore the need to restrict treatment to children whose illness is diagnosed with the use of stringent criteria.”

Researchers from Finland reported similar findings. With equally strict eligibility criteria, Dr. Paula Tähtinen and her associates at Turku University Hospital randomized 319 children aged 6-35 months who were diagnosed with AOM to receive amoxicillin-clavulanate or placebo for 7 days (N. Engl. J. Med. 2011;364:116-26).

The main outcome of the study was time to treatment failure from the first dose until the end-of-treatment visit on day 8. Treatment failure was a composite outcome consisting of six components: no improvement in overall condition by the first scheduled visit (day 3); a worsening of the child's condition at any time; no improvement in otoscopic signs by day 8; perforation of the tympanic membrane at any time; severe infection that required systemic open-label antimicrobial treatment at any time; or any other reason for discontinuing the study drug.

Dr. Tähtinen and her associates reported that a significantly lower rate of treatment failures occurred in children who received amoxicillin-clavulanate, compared with those who received placebo (18.6% vs. 44.9%, respectively). The difference in treatment failures was already apparent on day 3 in 13.7% of children who received amoxicillin-clavulanate, compared with 25.3% of those who received placebo. They also reported that overall, amoxicillin-clavulanate reduced the progression to treatment failure by 62% (hazard ratio 0.38) and the need for rescue treatment by 81% (HR 0.19).

In terms of side effects, the prevalence of diarrhea and eczema in the amoxicillin-clavulanate group was 47.8% and 8.7%, respectively, which was statistically higher than the rates in the placebo group (26.6% vs. 3.2%).

Going forward, they hypothesized, the identification of prognostic markers, “together with the use of stringent diagnostic criteria, could reduce the use of antimicrobial agents in the treatment of acute otitis media. Reduced use of antimicrobial agents may limit the development of resistant bacteria and increase the chances that the subsequent use of antimicrobial agents, when truly indicated, would be beneficial.”

Dr. Klein noted in his editorial that since physicians “cannot determine at the onset of the illness which child is likely to benefit from antimicrobial therapy, we need to consider these data as applicable to all young children in whom a certain diagnosis of acute otitis media has been made. Is acute otitis media a treatable disease? The investigators in Pittsburgh and Turku have provided the best data yet to

answer the question, and the answer is yes; more young children with a certain diagnosis of acute otitis media recover more quickly with an appropriate antimicrobial agent.”

Dr. Hoberman disclosed that he has received honoraria and travel expense reimbursement from GlaxoSmithKline. One of the other study authors, Dr. Ellen R. Wald, disclosed that she has received grant support from Merck and GlaxoSmithKline. Dr. Jack Paradise disclosed that he received a consulting fee from University of Pittsburgh Medical Center. The study was supported by a grant

from the National Institute of Allergy and Infectious Diseases.

The Turku study was supported by the Fellowship Award of the European Society for Pediatric Infectious Diseases. It also was supported by grants from the Foundation for Pediatric Research; Research Funds from Specified Government Transfers; the Jenny and Antti Wihuri Foundation; the Paulo Foundation; the Maud Kuistila Memorial Foundation; the Emil Aaltonen Foundation; the Finnish Cultural Foundation, Varsinais-Suomi Regional Fund; the Turku University Hospital Research Foundation; and the

Finnish-Norwegian Medical Foundation. One of the other study authors, Dr. Aino Ruohola, disclosed that he received support for the travel to meetings for the study or other purposes from the Finnish Society of Infectious Disease Specialists, and that Inverness Medical Point of Care Diagnostics, Binax Inc. donated Binax NOW *Streptococcus pneumoniae* test for the study project. Dr. Olli Ruuskanen disclosed that he had been a consultant for Abbott and Novartis.

Dr. Klein disclosed that he received honoraria from Innovia Medical from 2005 to 2008. ■

**It's here!**  
**MOXEZA™**  
 (moxifloxacin HCl ophthalmic solution) 0.5% as base

Introducing  
 the new morning & night  
 bacterial conjunctivitis treatment.

BID<sup>1</sup>

For patients  
 4 months and up.<sup>1</sup>

Now Available!

**INDICATIONS AND USAGE:**  
 MOXEZA™ Solution is a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: *Aerococcus viridans*\*, *Corynebacterium macginleyi*\*, *Enterococcus faecalis*\*, *Micrococcus luteus*\*, *Staphylococcus arlettae*\*, *S. aureus*, *S. capitis*, *S. epidermidis*, *S. haemolyticus*, *S. hominis*, *S. saprophyticus*\*, *S. warneri*\*, *Streptococcus mitis*\*, *S. pneumoniae*, *S. parasanguinis*\*, *Escherichia coli*\*, *Haemophilus influenzae*, *Klebsiella pneumoniae*\*, *Propionibacterium acnes*, *Chlamydia trachomatis*\* (\*efficacy for this organism was studied in fewer than 10 infections).

**DOSAGE AND ADMINISTRATION:**  
 Instill 1 drop in the affected eye(s) 2 times daily for 7 days.

**WARNINGS AND PRECAUTIONS:**

- Topical ophthalmic use only.
- Hypersensitivity and anaphylaxis have been reported with systemic use of moxifloxacin.
- Prolonged use may result in overgrowth of non-susceptible organisms, including fungi.
- Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis.

**ADVERSE REACTIONS:**  
 The most common adverse reactions reported in 1-2% of patients were eye irritation, pyrexia, and conjunctivitis.

Please see prescribing information on adjacent page.

**Alcon**  
 Licensed to Alcon, Inc. by Bayer Schering Pharma AG.  
 ©2010 Alcon, Inc. 11/10 VGZ10501JAD

**NEW Moxeza™**  
 (moxifloxacin HCl ophthalmic solution) 0.5% as base